The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15

[1]  M. Aihara,et al.  Omidenepag Isopropyl Versus Latanoprost in Primary Open-angle Glaucoma and Ocular Hypertension: ThePhase 3 AYAME Study. , 2020, American journal of ophthalmology.

[2]  A. Iwase,et al.  Factors Associated with Progression of Japanese Open-Angle Glaucoma with Lower Normal Intraocular Pressure. , 2019, Ophthalmology.

[3]  M. Araie,et al.  Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil , 2019, Journal of glaucoma.

[4]  M. Aihara,et al.  Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma , 2018, Japanese Journal of Ophthalmology.

[5]  Kenji Inoue,et al.  Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil , 2018, Japanese Journal of Ophthalmology.

[6]  Makoto Nakamura,et al.  Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma , 2018, Graefe's Archive for Clinical and Experimental Ophthalmology.

[7]  H. Tanihara,et al.  Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma , 2017, Expert opinion on pharmacotherapy.

[8]  K. Kadonosono,et al.  One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy , 2017, Graefe's Archive for Clinical and Experimental Ophthalmology.

[9]  A. Robin,et al.  Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. , 2017, American journal of ophthalmology.

[10]  H. Tanihara,et al.  Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study , 2017, Clinical Drug Investigation.

[11]  A. Tsujikawa,et al.  Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy , 2016, Advances in Therapy.

[12]  M. Araie,et al.  One‐year clinical evaluation of 0.4% ripasudil (K‐115) in patients with open‐angle glaucoma and ocular hypertension , 2016, Acta ophthalmologica.

[13]  Paula Anne Newman-Casey,et al.  Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up. , 2015, Ophthalmology.

[14]  M. Araie,et al.  Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials. , 2015, JAMA ophthalmology.

[15]  Richard A. Russell,et al.  Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial , 2015, The Lancet.

[16]  A. Tanna,et al.  Medical therapy for glaucoma: what to add after a prostaglandin analogs? , 2015, Current opinion in ophthalmology.

[17]  T. S. Wu,et al.  Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension , 2014, The Annals of pharmacotherapy.

[18]  L. Keinan-Boker,et al.  Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting , 2014, Family practice.

[19]  M. Araie,et al.  Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. , 2013, American journal of ophthalmology.

[20]  A. Rademaker,et al.  Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. , 2010, Archives of ophthalmology.

[21]  Paul P. Lee,et al.  Understanding the importance of IOP variables in glaucoma: a systematic review. , 2009, Survey of ophthalmology.

[22]  J. Lai,et al.  Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. , 2009, Ophthalmology.

[23]  J. Cox,et al.  Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review , 2008, British Journal of Ophthalmology.

[24]  A. Iwase,et al.  The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. , 2004, Ophthalmology.

[25]  M. C. Leske,et al.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. , 2002, Archives of ophthalmology.

[26]  M. Shirakashi,et al.  Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma , 2017, Advances in Therapy.